Stocks › HUMA
Humacyte, Inc.
HUMA·Nasdaq·
United States·USD
United States·USD$0.48
-0.02 (-4.40%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
HUMA
Humacyte, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HUMAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of HUMA by members of U.S. Congress · 17 on record · 5 in the last 12 months
Whale Activity
Position changes in HUMA reported for 2026-06-30 by 7 tracked institutional filers
- Increased2
- New2
- Held0
- Decreased3
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 10.1M | $7.9M | increased |
| BlackRock, Inc. | 4.8M | $3.8M | decreased |
| MILLENNIUM MANAGEMENT LLC | 1.9M | $1.5M | increased |
| CITADEL ADVISORS LLC | 1.4M | $1.1M | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 568.5K | $443K | decreased |
| Point72 Asset Management, L.P. | 53.7K | $42K | new |
| TWO SIGMA INVESTMENTS, LP | 29.5K | $23K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by HUMA insiders, by quarter · Form 4
Recent Insider Transactions
163 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Jones Keith AnthonyDirector · Director | Purchase | +10.0K | $0.56 | $6K | Sep 14, 2026 | Form 4 ↗ |
| Jones Keith AnthonyDirector · Director | Purchase | +10.0K | $0.69 | $7K | Aug 20, 2026 | Form 4 ↗ |
| Jones Keith AnthonyDirector · Director | Purchase | +30.0K | $0.59 | $18K | Aug 17, 2026 | Form 4 ↗ |
| Sebelius KathleenDirector | Purchase | +56.8K | $0.88 | $50K | May 19, 2026 | Form 4 ↗ |
| Parikh Shamik JChief Medical Officer | Sale | −45.9K | $0.90 | $41K | May 18, 2026 | Form 4 ↗ |
| Sander Dale A.CFO and Chief Corp. Dev. Off | Sale | −45.9K | $0.90 | $41K | May 18, 2026 | Form 4 ↗ |
| Constantino Michael T.Director | Purchase | +11.0K | $0.89 | $10K | May 18, 2026 | Form 4 ↗ |
| Sander Dale A.CFO and Chief Corp. Deve. Off. | Grant / award | +311.1K | $0.00 | $0 | Nov 16, 2025 | Form 4 ↗ |
| Parikh Shamik JChief Medical Officer | Grant / award | +311.1K | $0.00 | $0 | Nov 16, 2025 | Form 4 ↗ |
| Dougan Brady WDirector | Sale | −591.7K | $1.58 | $935K | Aug 20, 2025 | Form 4 ↗ |
| Niklason Laura EPresident, CEO and Director · Director | Sale | −591.7K | $1.58 | $935K | Aug 20, 2025 | Form 4 ↗ |
| Dougan Brady WDirector | Sale | −1.1M | $1.63 | $1.8M | Aug 19, 2025 | Form 4 ↗ |
| Niklason Laura EPresident, CEO and Director · Director | Sale | −1.1M | $1.63 | $1.8M | Aug 19, 2025 | Form 4 ↗ |
| Dougan Brady WDirector | Sale | −549.4K | $1.83 | $1.0M | Aug 18, 2025 | Form 4 ↗ |
| Niklason Laura EPresident, CEO and Director · Director | Sale | −549.4K | $1.83 | $1.0M | Aug 18, 2025 | Form 4 ↗ |
| Scheessele William JohnChief Commercial Officer | Purchase | +6,493 | $1.54 | $10K | Apr 14, 2025 | Form 4 ↗ |
| Sander Dale A.CFO and Chief Corp. Deve. Off. | Purchase | +20.0K | $1.53 | $31K | Apr 10, 2025 | Form 4 ↗ |
| Parikh Shamik JChief Medical Officer | Purchase | +7,500 | $1.55 | $12K | Apr 10, 2025 | Form 4 ↗ |
| Sebelius KathleenDirector | Purchase | +50.0K | $1.32 | $66K | Apr 8, 2025 | Form 4 ↗ |
| Green Charles BruceDirector | Purchase | +6,000 | $1.29 | $8K | Apr 8, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding HUMA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 7.7M | $6.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iSHARES TRUST | 3.9M | $2.3M | 0.00% | Mar 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $1.7M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $1.3M | 0.00% | Apr 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 1.4M | $1.1M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 839.3K | $1.1M | 0.00% | May 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 835.7K | $1.1M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 728.6K | $947K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF iSHARES TRUST | 1.1M | $675K | 0.01% | Mar 31, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 474.6K | $617K | 0.00% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list HUMA's shares (CUSIP 44486Q103), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Fresenius Medical Care AGSCHEDULE 13D/A · activist (13D) · 13.6M shares4.9%
Aug 18, 2026 · ↗ - Fresenius Medical Care Holdings, Inc.SCHEDULE 13D/A · activist (13D) · 13.6M shares4.9%
Aug 18, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 4.1M shares1.5%
Jul 28, 2026 · ↗ - Fresenius Medical Care AGSCHEDULE 13D/A · activist (13D) · 18.3M shares6.8%
Jul 13, 2026 · ↗ - Fresenius Medical Care Holdings, Inc.SCHEDULE 13D/A · activist (13D) · 18.3M shares6.8%
Jul 13, 2026 · ↗ - Anthony A. YoseloffSCHEDULE 13G · passive (13G) · 12.8M shares4.7%
Jun 22, 2026 · ↗ - Davidson Kempner Capital Management LPSCHEDULE 13G · passive (13G) · 12.8M shares4.7%
Jun 22, 2026 · ↗ - Davidson Kempner Arbitrage, Equities & Relative Value LPSCHEDULE 13G · passive (13G) · 12.6M shares4.7%
Jun 22, 2026 · ↗ - M.H. Davidson & Co.SCHEDULE 13G · passive (13G) · 232.7K shares0.1%
Jun 22, 2026 · ↗ - Fresenius Medical Care AGSCHEDULE 13D/A · activist (13D) · 18.3M shares6.8%
Jun 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming humacyte as client
- CAPITOL HILL CONSULTING GROUPHUMACYTE · 2026 Q2 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2026 Q1 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2025 Q4 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2025 Q3 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2025 Q3 · HCR, MMM, DEF—
Filing ↗
Government Contracts
Federal awards to Humacyte, Inc. · USAspending
No federal contract awards found for Humacyte, Inc..
U.S. Patents
Recent USPTO applications naming Humacyte, Inc.
No USPTO patent applications found for Humacyte, Inc..
Annual Financials
From HUMA's 10-K filings · XBRL
No annual XBRL figures on record for HUMA. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in HUMA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 12, 2026
EDGAR ↗ - 8-K · Items 3.01Delisting noticeJul 31, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 11, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 10, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 5, 2026
EDGAR ↗ - 8-K · Items 3.01Delisting noticeMay 8, 2026
EDGAR ↗
About Humacyte, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDURHAM, NC
IncorporatedDE
SEC CIK0001818382 ↗
Former namesAlpha Healthcare Acquisition Corp.